Hypothesis

Persistent low‑grade nociceptor firing releases CGRP and substance P that trigger a mild, systemic hormetic stress response. This response activates PI3K/Akt, AMPK and SIRT1 pathways, leading to enhanced autophagy, NAD+ turnover and ROS‑mediated Nrf2 signaling. When nociceptor signaling is chronically silenced—by gene therapy, pharmacological blockers or genetic ablation—the hormetic cascade blunts, resulting in accelerated epigenetic aging, reduced healthspan and shortened lifespan.

Mechanistic Rationale

1. Nociceptor‑derived neuropeptides act on vascular endothelium and immune cells, promoting PI3K/Akt‑dependent survival signals that cross‑talk with mTORC2 and FOXO phosphorylation, a node known to regulate stress resistance.
2. Substance P‑mediated neurokinin‑1 receptor activation stimulates PLC‑β, generating IP3‑Ca2+ fluxes that activate CaMKKβ‑AMPK signaling, boosting mitochondrial biogenesis and autophagic flux.
3. The concurrent low‑level ROS produced by nociceptor‑driven NADPH oxidase activity serves as a mitohormetic cue, stabilizing Nrf2 and up‑regulating antioxidant genes (HO‑1, NQO1).
4. Chronic suppression removes these cues, shifting the balance toward mTORC1‑driven anabolism, diminished NAD+ salvage, and accumulation of senescent cells marked by p16^INK4a and SASP.
5. Evidence that mice lacking CGRP and substance P retain normal nociception suggests the longevity‑modulating function can be uncoupled from pain perception, supporting selective modulation.

Testable Predictions

• Mice with nociceptor‑specific TRPV1 knockdown will show decreased lifespan and accelerated epigenetic clock (e.g., increased Horvath‑mouse DNA methylation age) despite normal acute pain thresholds.
• Conversely, nociceptor‑specific overexpression of CGRP will extend median lifespan and improve healthspan metrics (grip strength, frailty index) without altering pain sensitivity.
• Pharmacologic blockade of TRPV1 with long‑acting antagonists will recapitulate the lifespan shortening seen in genetic models, and co‑administration of a low‑dose Nrf2 activator will rescue the phenotype.
• In humans, individuals undergoing long‑term localized analgesic nerve blocks (e.g., chronic epidural infusion) will exhibit faster accumulation of epigenetic age markers in peripheral blood compared with matched controls.

Experimental Design

Model: Adult (8‑week) C57BL/6J mice. Groups: (1) Control AAV‑GFP; (2) AAV‑Cre in TRPV1^fl/fl mice (nociceptor‑specific TRPV1 KO); (3) AAV‑CGRP overexpression in nociceptors (using Advillin promoter); (4) TRPV1 KO + CGRP overexpression (rescue); (5) WT + systemic TRPV1 antagonist (A‑889425) delivered via osmotic pump for 6 months. Readouts: Survival curves, frailty index, grip strength, gait analysis; tissue collection at 12 and 24 months for epigenetic clock (bisulfite sequencing of blood and liver), senescence‑associated β‑gal, p16 immunostaining, autophagic flux (LC3‑II/I ratio, p62), NAD+/NADH ratio, Nrf2 target gene expression. Statistical: Log‑rank test for survival; two‑way ANOVA for longitudinal phenotypes; p<0.05 considered significant.

If the data show that reducing nociceptor output shortens lifespan and accelerates epigenetic aging while preserving neuropeptide levels rescues these effects, the hypothesis gains support. If lifespan remains unchanged, the premise that basal pain signaling is a longevity signal would be falsified.